Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.
Michael Bitzer
No relevant relationships to disclose
Marius Horger
No relevant relationships to disclose
Tom M Ganten
No relevant relationships to disclose
Ulrich M Lauer
No relevant relationships to disclose
Marcus A Woerns
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Jens T Siveke
No relevant relationships to disclose
Matthias M. Dollinger
No relevant relationships to disclose
Guido Gerken
No relevant relationships to disclose
Henning Wege
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Edoardo G Giannini
Research Funding - 4SC
Other Remuneration - 4SC
Vittorina Zagonel
No relevant relationships to disclose
Umberto Cillo
No relevant relationships to disclose
Franco Trevisani
Consultant or Advisory Role - Bayer
Honoraria - Marben; Sudler & Hennessey
Research Funding - Bayer
Other Remuneration - Bayer
Armando Santoro
No relevant relationships to disclose
Vincenzo Montesarchio
No relevant relationships to disclose
Bernhard Hauns
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Julia Asche
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
RĂ¼diger Jankowsky
Employment or Leadership Position - 4SC
Anna Mais
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Bernd Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC